Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Long-term remissions after CD19 chimeric antigen receptor (CAR) T cell therapy for refractory/relapsed CD19+ B cell acute lymphoblastic leukemia (B-ALL) are elusive.1-6 A high percentage of subjects achieve initial complete remission (CR), but half of subjects experience a recurrence of disease within 6-18 months from CAR T cell infusion.1, 4, 7

  • 123456 Profile photo of Madelyn

    Via @BldCancerDoc “small retrospective analysis, but consolidative HCT assoc with higher LFS following CD19 #CARTcell induced remission for ALL patients with no prior history of HCT or for those with short functional CAR T cell persistence”